Earnings Tell The Story For Neurocrine Biosciences, Inc. (NASDAQ:NBIX) As Its Stock Soars 27%
May 11
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 11, 2025
DataAggregated Company Financials
Companies563
- 7D-9.0%
- 3M-12.4%
- 1Y-15.0%
- YTD-10.3%
Over the last 7 days, the Biotech industry has dropped 9.0%, driven by AbbVie declining 7.0%. Meanwhile, Neurocrine Biosciences actually outperformed within the industry, gaining 5.5% in the last week. Overall the industry is down 15% in 12 months. Looking forward, earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 11 May 2025 | US$861.2b | US$154.9b | -US$24,538,327,634.73 | 16.7x | -35.1x | 5.6x |
| Tue, 08 Apr 2025 | US$735.7b | US$118.6b | -US$37,003,812,363.33 | 20.2x | -19.9x | 6.2x |
| Thu, 06 Mar 2025 | US$833.3b | US$119.0b | -US$37,174,684,124.22 | 16.7x | -22.4x | 7x |
| Sat, 01 Feb 2025 | US$998.3b | US$149.5b | -US$26,306,804,829.57 | 17.2x | -37.9x | 6.7x |
| Mon, 30 Dec 2024 | US$977.8b | US$149.9b | -US$26,372,711,577.30 | 16.2x | -37.1x | 6.5x |
| Wed, 27 Nov 2024 | US$1.0t | US$150.0b | -US$26,586,070,085.45 | 16.4x | -38.7x | 6.9x |
| Fri, 25 Oct 2024 | US$884.2b | US$113.1b | -US$36,026,588,945.48 | 20.7x | -24.5x | 7.8x |
| Sun, 22 Sep 2024 | US$920.0b | US$113.2b | -US$35,985,348,157.41 | 21.9x | -25.6x | 8.1x |
| Tue, 20 Aug 2024 | US$883.3b | US$113.2b | -US$35,828,678,074.72 | 23.2x | -24.7x | 7.8x |
| Thu, 18 Jul 2024 | US$1.2t | US$164.5b | -US$28,053,331,413.34 | 29.4x | -43.2x | 7.4x |
| Sat, 15 Jun 2024 | US$1.2t | US$164.4b | -US$28,065,533,148.41 | 27.3x | -41.3x | 7.1x |
| Mon, 13 May 2024 | US$1.1t | US$164.6b | -US$26,961,785,793.98 | 23.3x | -41.2x | 6.7x |
| Wed, 10 Apr 2024 | US$1.1t | US$164.4b | -US$23,371,088,407.86 | 21.5x | -48.3x | 6.9x |
| Fri, 08 Mar 2024 | US$1.2t | US$167.5b | -US$21,885,421,990.22 | 18.8x | -54.5x | 7.1x |
| Sun, 04 Feb 2024 | US$1.4t | US$203.9b | -US$24,418,168,728.00 | 19.2x | -58.9x | 7.1x |
| Tue, 02 Jan 2024 | US$1.4t | US$204.9b | -US$22,203,182,413.00 | 19.8x | -62.5x | 6.8x |
| Thu, 30 Nov 2023 | US$1.2t | US$204.8b | -US$22,009,160,710.00 | 18.1x | -55.4x | 6x |
| Sat, 28 Oct 2023 | US$1.2t | US$206.6b | -US$15,166,070,486.00 | 16.3x | -77.7x | 5.7x |
| Mon, 25 Sep 2023 | US$1.3t | US$207.5b | -US$12,879,333,723.00 | 17.1x | -97.9x | 6.1x |
| Wed, 23 Aug 2023 | US$1.3t | US$207.6b | -US$12,453,450,426.00 | 17.4x | -102.7x | 6.2x |
| Fri, 21 Jul 2023 | US$1.1t | US$186.5b | -US$16,008,267,080.00 | 12.7x | -71.5x | 6.1x |
| Sun, 18 Jun 2023 | US$1.2t | US$186.3b | -US$16,045,332,946.00 | 12.1x | -72.3x | 6.2x |
| Tue, 16 May 2023 | US$1.2t | US$191.8b | -US$12,215,533,598.00 | 13.8x | -95.7x | 6.1x |
| Thu, 13 Apr 2023 | US$1.2t | US$198.5b | -US$3,250,698,650.00 | 14x | -357.1x | 5.8x |
| Sat, 11 Mar 2023 | US$1.1t | US$199.3b | -US$4,751,094,936.00 | 14.9x | -230.3x | 5.5x |
| Mon, 06 Feb 2023 | US$1.2t | US$202.3b | US$1.9b | 16.3x | 624.5x | 5.7x |
| Wed, 04 Jan 2023 | US$1.1t | US$203.2b | US$1.6b | 14.3x | 722.7x | 5.6x |
| Fri, 02 Dec 2022 | US$1.2t | US$202.6b | US$1.4b | 15.2x | 814.9x | 5.7x |
| Sun, 30 Oct 2022 | US$1.1t | US$205.9b | US$7.4b | 14.3x | 148.7x | 5.3x |
| Tue, 27 Sep 2022 | US$999.8b | US$205.8b | US$5.5b | 13.8x | 181.9x | 4.9x |
| Thu, 25 Aug 2022 | US$1.1t | US$206.2b | US$7.3b | 16x | 147.3x | 5.2x |
| Sat, 23 Jul 2022 | US$1.1t | US$211.4b | US$11.3b | 16.6x | 95.9x | 5.1x |
| Mon, 20 Jun 2022 | US$952.1b | US$212.2b | US$10.9b | 14.8x | 87x | 4.5x |
| Wed, 18 May 2022 | US$999.2b | US$212.2b | US$10.9b | 16.4x | 91.7x | 4.7x |
Price to Earnings Ratio
91.7x
Current Industry PE
- Investors are pessimistic on the American Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 6.3x is higher than the industry's current PS ratio of 5.6x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 10.0% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.26% | |
| Healthcare | -4.28% | |
| Biotech | -8.98% | |
| Biotech | -8.98% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | US$115.71 | 5.5% +US$599.8m | -15.4% | PE37.4x | |
| HALO Halozyme Therapeutics | US$65.87 | 7.6% +US$557.6m | 52.7% | PE16.7x | |
| ALVO Alvotech | US$9.68 | 17.8% +US$440.6m | -27.6% | PE30.3x | |
| ACAD ACADIA Pharmaceuticals | US$17.44 | 17.0% +US$432.0m | 14.4% | PE12.8x | |
| UTHR United Therapeutics | US$301.42 | 2.3% +US$307.6m | 14.1% | PE11.2x |
